The “world's first” graphene-based neurochip was implanted in a cancer patient

The Spanish startup successfully demonstrated the capabilities of its graphene "brain-computer’ interface" (BCI) for precise surgical operation on tumors.

INBRAIN Neuroelectronics, a company specializing in brain-computer interface therapy, has successfully implanted its cortical interface in a patient. According to the press release, this is the “world's first case of using a cortical interface in a patient undergoing resection of a brain tumor.” Interestingly, this BCI technology was able to detect the difference between healthy and cancerous brain tissue at a microscopic level. The procedure was performed at Salford Royal Hospital in Manchester, UK.

«The world's first human application of a graphene-based BCI highlights the transformative impact of graphene-based neural technologies in medicine. This clinical milestone opens a new era for BCI technology, paving the way for progress in both deciphering neural signals and their application as a therapeutic intervention. said Carolina Aguilar, CEO and co-founder of INBRAIN Neuroelectronics.

The device is based on graphene – excellent material with exceptional properties. Graphene-based materials consist of a single layer of carbon atoms. Graphene is extremely thin and at the same time incredibly strong. Its unique electrical and mechanical properties combine to make it an ideal material for neural interfaces.

"We record brain activity in areas where traditional metals and materials have problems with signal transmission accuracy. Graphene provides an ultra-high density for sensing and stimulation, which is critical for performing high-precision resections while preserving the patient's functional capabilities, such as movement, speech or cognition, – said Dr. David Koop, the neurosurgeon who performed the procedure.

200% Deposit Bonus up to €3,000 180% First Deposit Bonus up to $20,000

After extensive testing and development, the company announced the start of human trials in July 2024. The trials will involve 8-10 patients to assess the safety of graphene in direct contact with the human brain. "The study will also aim to demonstrate the superiority of graphene over other materials in deciphering the functionality of the brain both in the waking state and in the sleep state", – said Kostas Kostarelos, co-founder of INBRAIN Neuroelectronics.

The company has combined graphene, artificial intelligence (AI), and advanced semiconductor technology to create a new type of BCI therapy. This therapy is designed to be minimally invasive. At most, the BCI-Tx platform uses graphene for high-resolution brain signal recording and "adaptive neuroelectronic therapy".

The device can also identify specific patterns of brain activity, known as biomarkers, that are associated with’ various neurological conditions. This information can be used to diagnose and monitor diseases.

According to the press release, the platform can also precisely stimulate specific areas of the brain, including the cortex and subcortical structures, to “rebalance the neural network.” "INBRAIN is at the forefront of precision neurology, integrating BCI decoding with high-precision neuromodulation to restore function and alleviate symptoms, providing continuous, personalized treatment to maximize benefits while minimizing side effects,– Aguilar noted.

The company suggests that this brain implant could significantly benefit people suffering from Parkinson's disease. According to INBRAIN, approximately 30% of the global population suffers from neurological disorders.

Several companies, including Elon Musk's Neuralink, are actively involved in the development of BCI technology. In recent years, BCIs have enabled breakthroughs in medical diagnosis, communication for people with speech impairments, and even control of external devices such as robotic limbs by recording and interpreting brain signals.